Elicio Therapeutics, Inc. — Net Income by Fiscal Year
6 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/fa5b8723-215b-4a22-92b4-eb7063b9e92c/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-39.6M | 2025-01-01 – 2025-12-31 | evidence 0001601485-26-000027 |
| FY 2024 | $-51.9M | 2024-01-01 – 2024-12-31 | evidence 0001601485-25-000049 |
| FY 2023 | $-35.2M | 2023-01-01 – 2023-12-31 | evidence 0001601485-24-000023 |
| FY 2022 | $-28.2M | 2022-01-01 – 2022-12-31 | evidence 0001601485-24-000023 |
| FY 2021 | $-54.6M | 2021-01-01 – 2021-12-31 | evidence 0001601485-22-000022 |
| FY 2020 | $-80.1M | 2020-01-01 – 2020-12-31 | evidence 0001601485-22-000022 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Elicio Therapeutics, Inc. — all facts · Revenue · Operating Income